Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 186 results
  • Sort by Sort ascending
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location NCT ID

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) Phase3 Australia
China
France
Germany
Italy
Japan
Netherlands
South Korea
Spain
United States
View all

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES) Phase2 United States

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

Heterozygous or Homozygous Familial Hypercholesterolemia Phase3 Taiwan

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) Phase1 Japan

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive Phase2 Australia
Brazil
Canada
China
France
Germany
Italy
Japan
Netherlands
Poland
South Korea
Spain
United States
View all

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population

Hidradenitis Suppurativa Italy

REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria (PNH) Italy

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF) Phase3 Argentina
Australia
China
India
Malaysia
South Korea
Switzerland
Taiwan
Turkey (Türkiye)
United States
View all

A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

Heart Failure With Reduced Ejection Fraction Phase1 Canada
United States

A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy

Secondary Malignancies of T-cell Origin Japan